Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P140029/S054

Restylane Contour

Q-Med AB · Decision date Mar 20, 2026

FDA DECISIONP140029/S054

What did the FDA approve?

FDA records P140029/S054 as a supplement to PMA P140029, with the supplement type “Panel Track”. The recorded decision is approval, dated Mar 20, 2026.

FDA approval order statement

Approval for expanding the indications of Restylane Contour for correction of temple hollowing in patients over the age of 21.
Regulatory pathway
PMA supplement
Supplement type
Panel Track
Clinical specialty
General, Plastic Surgery
Decision date
Mar 20, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P140029/S054
Regulatory pathway
PMA supplement
Applicant
Q-Med AB
Product code
LMH
Decision code
APPR
Decision date
Mar 20, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Applicant
Q-Med AB
Product code
LMH
FDA device class
3

For the original device and its historical approval scope, see PMA P140029. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P140029 · Original PMA

    Restylane Refyne, Restylane Defyne

  2. P140029/S054 received

    Application receipt date recorded by FDA.

  3. P140029/S055 · Related supplement

    Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour

  4. P140029/S054 · FDA decision

    Panel Track

  5. P140029/S056 · Related supplement

    Restylane Refyne, Restylane Defyne, Restylane Kysse and Restylane Contour

Timeline entries are records held by MedtechLedger for P140029. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P140029

Product / regulatory recordCompanyPathwayDecision dateSource
Q-Med ABPMA approvalDec 9, 2016FDA
Q-Med ABPMA supplementSep 26, 2025FDA
Q-Med ABPMA supplementApr 14, 2026FDA
Restylane ContourP140029/S057
Q-Med ABPMA supplementMay 15, 2026FDA
Restylane ContourP140029/S058
Q-Med ABPMA supplementSep 18, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Q-Med AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seminariegatan 21, Uppsala, S-752 28

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records